Home/ Stocks/ EBS

Emergent Biosolutions, Inc.

EBS XNYS

$4.84 -0.46 (-8.66%) ▼ 15-min delayed

Open

$5.40

High

$5.55

Low

$4.81

Volume

3.14M

Market Cap

$272.26M

About Emergent Biosolutions, Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 900 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$156.10M	$6.80M	$0.13
FY 2025	$742.90M	$52.60M	$0.98
Q3 2025	$231.10M	$51.20M	$0.96
Q2 2025	$140.90M	$-12,000,000	$-0.22

Related Market News

No specific coverage for EBS yet. Check out our latest market news or earnings calendar.

Get EBS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Emergent Biosolutions, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.